Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SanBio Co ( (JP:4592) ) has issued an update.
SanBio Co. reported its consolidated financial results for the six months ending July 31, 2025, showing a net loss attributable to owners of the parent amounting to ¥1,997 million, an increase from the previous year’s loss. The company’s equity ratio decreased from 45.1% to 33.5%, indicating a decline in financial stability. The forecast for the fiscal year ending January 31, 2026, anticipates continued losses, with a net income per share projected at ¥(56.17).
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2100.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. It focuses on developing regenerative cell therapies to address unmet medical needs, particularly in the field of neurological disorders.
Average Trading Volume: 2,887,422
Technical Sentiment Signal: Buy
Current Market Cap: Yen170.1B
See more insights into 4592 stock on TipRanks’ Stock Analysis page.